
category:watercooler
Shortages threaten corporate profits, likely to end soon
We think the GLP1 shortage is going to end in the first half of 2025. Here's why.
category:watercooler
We think the GLP1 shortage is going to end in the first half of 2025. Here's why.
category:news
The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.
government
The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?
drug:ozempic
Learn the major differences between Ozempic (Semaglutide) and Mounjaro (Tirzepatide)